

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 02-482-C	FOR FURTHER ACTION		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US03/29078	International filing date (day/month/year) 16 September 2003 (16.09.2003)	Priority date (day/month/year) 20 September 2002 (20.09.2002)	

International Patent Classification (IPC) or national classification and IPC

IPC: Please See Continuation Sheet

USPC: 435/189,4,6,18,69,1,71,1,252,3,320,1;536/23,2;530/350,387,9;424/94,4

Applicant

PROMEGA CORPORATION

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of — sheets.

3. This report contains indications relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of report with regard to novelty, inventive step and industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

Date of submission of the demand 16 March 2004 (16.03.2004)	Date of completion of this report 27 September 2006 (27.09.2006)
Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/ US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201	Authorized officer Ponnathapu Achutamurthy Telephone No. 571-272-1600

Form PCT/IPEA/409 (cover sheet)(July 1998)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US03/29078

I. Basis of the report

1. With regard to the elements of the international application:*

the international application as originally filed.

the description:
pages 1-75 as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.

the claims:
pages 76-103, as originally filed
pages NONE, as amended (together with any statement) under Article 19
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.

the drawings:
pages 1-26, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.

the sequence listing part of the description:
pages NONE, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

the language of publication of the international application (under Rule 48.3(b)).

the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

contained in the international application in printed form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

the description, pages NONE

the claims, Nos. NONE

the drawings, sheets/fig NONE

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. STATEMENT**

Novelty (N)	Claims <u>1-131 and 143-167</u>	YES
	Claims <u>132-142</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-167</u>	NO
Industrial Applicability (IA)	Claims <u>1-167</u>	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 132-142 lack novelty under PCT Article 33(2) as being anticipated by Geiger et al.

Geiger et al. discloses D-luciferin derivatives having the formula recited in claim 135 (abstract and Columns 2-3). Therefore, the reference anticipates claims 132-142.

Claims 1-131 and 143-167 lack an inventive step under PCT Article 33(3) as being obvious over Chrespi et al. in view of Geiger et al. Chrespi et al. discloses a method for measuring cytochrome P450 enzymatic activity using a luminogenic molecule. Chrespi et al. does not disclose said method using a luciferin derivatives having the formula recited in claim 112. However, Geiger et al. discloses such luciferin derivatives that are used in immunoassays. Therefore, it would have been obvious to combine the two teachings in order to measure cytochrome P450 enzymatic activity using a luminogenic molecule, such as luciferin derivatives.

Claims 1-167 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US03/29078

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of IPC:
C12N 9/02(2006.01),1/20(2006.01),15/00(2006.01);C12Q 1/00(2006.01),1/34(2006.01),1/68(2006.01);C12P 21/06(2006.01),21/04(2006.01);A61K 38/44(2006.01);C07H 21/04(2006.01);C07K 1/00(2006.01),16/00(2006.01)